Longer Term Outcomes With Pembrolizumab Plus Axitinib for Advanced RCC
Real-world treatment outcomes of 1L axitinib + pembrolizumab in patients with advanced RCC in the USПодробнее
Axitinib plus pembrolizumab in advanced RCCПодробнее
Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее
Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCCПодробнее
Promising results for axitinib and pembrolizumab in advanced renal cell cancerПодробнее
Extended Follow-Up From a Trial of Pembrolizumab Plus Axitinib for Advanced Renal Cell CarcinomaПодробнее
Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCCПодробнее
Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCCПодробнее
Updated Results of a Clinical Trial Evaluating Pembrolizumab + Axitinib for Frontline Adv RCCПодробнее
Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCCПодробнее
KEYNOTE-426 studyПодробнее
Pembrolizumab monotherapy and pembro-axitinib for RCCПодробнее
Combining avelumab and axitinib in advanced renal cell carcinoma (RCC)Подробнее
Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCCПодробнее
Drs. Rini, Wallis on a 5-Year Analysis of KEYNOTE-426 for Advanced Clear Cell RCCПодробнее
Dr. Rini on Pembrolizumab Plus Axitinib in RCCПодробнее
Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCCПодробнее
Phase I/II study of nivolumab and axitinib for advanced RCCПодробнее
Exciting potential of pembrolizumab combined with axitinib for kidney cancerПодробнее
